Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Americas Cancer Immunotherapy Market to Reach $125.32 Billion by 2031, Driven by R&D Advances and Expanding Clinical Adoption

globenewswire.com
MRK Merck received FDA Breakthrough Therapy Designation for its personalized cancer vaccine, highlighting accelerated innovation and progress in immuno-oncology. BMY Bristol Myers Squibb's agreement with Cellares for manufacturing capacity suggests a focus on scaling cell-therapy production, supporting market growth and innovation.

Americas Cancer Immunotherapy Market to Reach $125.32 Billion by 2031, Driven by R&D Advances and Expanding Clinical Adoption Dublin, Aug. 10, 2026 (GLOBE NEWSWIRE) -- The "America Cancer Immunotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

The Americas cancer immunotherapy market is estimated at USD 82.84 billion in 2026, up from USD 76.26 billion in 2025. The market is forecast to reach USD 125.32 billion by 2031, registering a compound annual growth rate of 8.63% from 2026 to 2031.

Market growth is supported by rising cancer incidence, greater adoption of immune-checkpoint inhibitors, expanding regulatory approvals, biomarker-led treatment selection, and continued investment in advanced immuno-oncology research. The report analyzes the market by therapy type, cancer type, end user, route of administration, and geography across North America and South America. Forecasts are provided in terms of value in U.S. dollars.

Americas Cancer Immunotherapy Market Trends and Insights

R&D Productivity Accelerates Clinical Development

AI-enhanced biomarker analytics, adaptive clinical trial protocols, and automated cell-therapy manufacturing are shortening development timelines across the Americas cancer immunotherapy market. Merck and Moderna received FDA Breakthrough Therapy Designation for the mRNA-4157/V940 personalized cancer vaccine in high-risk melanoma approximately two years after first-in-human dosing, highlighting the accelerating pace of immunotherapy innovation.

Automated production platforms are also addressing manufacturing constraints. Bristol Myers Squibb reserved manufacturing capacity with Cellares through an agreement valued at USD 380 million, supporting faster and more scalable cell-therapy production. These advances are improving capital efficiency, reducing late-stage development risk, and enabling more novel candidates to progress into pivotal clinical studies.

Rising Cancer Incidence Sustains Treatment Demand

An aging population in North America, changing lifestyle patterns, and infection-associated cancers in parts of South America continue to increase demand for cancer immunotherapy. Healthcare systems are responding by expanding immuno-oncology services, diagnostic infrastructure, and specialist treatment capacity, particularly in major urban centers.

Biomarker-based patient selection and advances in tumor profiling are also supporting more precise treatment decisions. The expansion of immunotherapy into adjuvant and neoadjuvant settings is increasing the addressable patient population and strengthening the market's long-term revenue outlook.

Safety and Cost Remain Key Market Constraints

Immune-related adverse events remain a significant challenge, particularly with combination regimens. Grade 3-4 adverse events were recorded in 52.8% of checkpoint-inhibitor recipients in referenced 2025 studies. Hospitals require multidisciplinary care teams, predictive biomarkers, early-warning systems, and enhanced monitoring protocols to manage these risks.

High treatment and management costs may also slow adoption among smaller healthcare providers. Prolonged hospitalization, immunosuppressant use, specialist care requirements, and complex manufacturing processes can increase the total cost of therapy. Other market factors assessed in the report include the expansion of FDA and ANVISA approvals and the growing uptake of immune-checkpoint inhibitors.

Therapy Type and Cancer Segment Analysis

Monoclonal antibodies accounted for 44.90% of Americas cancer immunotherapy market share in 2025, reflecting their established use across solid tumors and hematologic malignancies. Cell-based therapies are projected to record the fastest growth, with a 17.70% CAGR, supported by expanding CAR-T indications, next-generation natural killer cell products, and improvements in automated manufacturing.

Combination regimens integrating monoclonal antibodies, cell therapies, and immunomodulators are being developed to address treatment resistance. Bispecific platforms, personalized neoantigen vaccines, and oncolytic virus therapies are also contributing to a more diversified immunotherapy pipeline through 2031.

Lung cancer represented 26.23% of the market in 2025, supported by the widespread use of checkpoint inhibitors in non-small-cell lung cancer. Hematologic malignancies are expected to register the highest CAGR of 16.64% as CAR-T therapies and bispecific T-cell engagers gain traction in refractory blood cancers. Research in prostate cancer, melanoma, and other solid tumors is further broadening the clinical scope of cancer immunotherapy.

Complete Report Scope

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this report visit https://www.researchandmarkets.com/r/q3zxh6

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.